![Mike Woolcock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mike Woolcock
Direttore/Membro del Consiglio presso Biosimilars Canada
Profilo
Mike Woolcock has a current job as Vice Chairman at Biosimilars Canada.
Posizioni attive di Mike Woolcock
Società | Posizione | Inizio |
---|---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Commercial Services |
- Borsa valori
- Insiders
- Mike Woolcock